Guselkumab (Tremfya)

Read full text Summarise with VIRAT
Authors: CDA-AMC
Cited by: 0
References: 88

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Induction: Guselkumab (Tremfya) 200 mg/20 mL vial of sterile solution administered through IV infusion. Maintenance: Guselkumab (Tremfya) 100 mg/1 mL pre-filled syringe, 100 mg/1 mL patient-controlled injector, 200 mg/2 mL pre-filled syringe, and 200 mg/2 mL pre-filled pen administered by subcutaneous injection. Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis.

Fields of Study & Subjects

Inflammatory Bowel Disease Health Systems Economic Evaluations Quality of Life Pharmaceutical Economics and Policy

Publication details

Journal / source
Canadian Journal of Health Technologies
Volume
6
Issue
3
Publication date
27 March 2026
Language
EN